GRI
GRI Bio, Inc.·Healthcare
2.45
3.814%(+0.09)
Market ClosedLast Updated: — ET
52W L: $2.1052W H: $80.36
GRI NEWS
globenewswire.com
3d ago
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
globenewswire.com
Feb 17
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
Access the “What This Means” segment here
globenewswire.com
Feb 5
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST
globenewswire.com
Feb 4
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026
defenseworld.net
Feb 1
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
Immuneering (NASDAQ: IMRX - Get Free Report) and GRI Bio (NASDAQ: GRI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Immuneering and GRI Bio's
globenewswire.com
Jan 28
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”), further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621. Newly reported RNA-sequencing differential gene expression data demonstrate that treatment with GRI-0621 resulted in significant improvement across genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair compared to placebo.
